10x Genomics has raised its revenue guidance for 2026, citing demand for its Atera product that exceeded internal expectations.
The company indicated that the stronger-than-anticipated uptake of Atera was the primary factor behind the upward revision to its financial outlook for the current year.
No specific figures for the new revenue target or the magnitude of the increase were provided in the available reporting.
Details regarding the timing of the announcement or additional financial metrics were not included in the source material.
